Kirsten Lawson and Douglas Badenoch review the new randomised controlled trial by Cleare et al, published today in The Lancet Psychiatry, directly comparing the clinical and cost effectiveness of lithium and quetiapine as augmentation treatments for patients with ‘treatment resistant depression’.
The post Quetiapine may pip lithium to the post for augmentation in ‘treatment resistant depression’: results from the LQD study appeared first on National Elf Service.
